MaxVal Publishes Advanced CRISPR-Cas9 Report

Following the publication of our recent Technology Landscape study on CRISPR-Cas9, MaxVal announces the latest advanced publication on the genome editing system, CRISPR, which has become an extremely important tool in medical research.  The demonstration of the reprogrammable nature of Cas9 served as a catalyst to widespread adoption of CRISPR systems in biomedical and agricultural research.  The potential benefits of CRISPR gene editing in several challenging diseases such as Alzheimer’s, cancer, and numerous autoimmune diseases are being explored by researchers. MaxVal’s CRISPR report is now available through Patent LiveScape™, an analysis and reporting service that provides clients with interactive reports which extract

Continue reading

Acquisition and Predictive Analysis

It’s been a busy year for mergers and acquisitions, with a number of billion dollar deals that happened. We tracked and analyzed over 700 Mergers & Acquisitions that occurred in 2017 and extracted the 20 largest deals across 9 industries, valued above $5 B. $274.9B in large M&A transactions took place in 2017. 42% of the transactions occurred in the Medical/Pharma Sector totaling $86.6 B across 8 events. 21% of the transactions occurred in the Energy Sector totaling $28.3 B across 4 events. The largest acquisition in the most active sector: Medical equipment/Pharma was J&J | Actelion at $30B. The largest acquisition

Continue reading